|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-9-20
|
|
pubmed:abstractText |
A single-institution Phase I clinical trial was conducted to determine the maximum tolerated dose (MTD) and define the safety profile of temozolomide and capecitabine when used in combination to treat brain metastases from breast cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
(c) 2006 American Cancer Society.
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
107
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1348-54
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:16909414-Adult,
pubmed-meshheading:16909414-Aged,
pubmed-meshheading:16909414-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16909414-Brain Neoplasms,
pubmed-meshheading:16909414-Breast Neoplasms,
pubmed-meshheading:16909414-Cohort Studies,
pubmed-meshheading:16909414-Dacarbazine,
pubmed-meshheading:16909414-Deoxycytidine,
pubmed-meshheading:16909414-Dose-Response Relationship, Drug,
pubmed-meshheading:16909414-Drug Administration Schedule,
pubmed-meshheading:16909414-Fatigue,
pubmed-meshheading:16909414-Female,
pubmed-meshheading:16909414-Fluorouracil,
pubmed-meshheading:16909414-Humans,
pubmed-meshheading:16909414-Middle Aged,
pubmed-meshheading:16909414-Nausea,
pubmed-meshheading:16909414-Treatment Outcome,
pubmed-meshheading:16909414-Vomiting
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma.
|
|
pubmed:affiliation |
Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. rivera@edgardoriveramd.com
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial, Phase I
|
